Press Releases

Aurinia Announces Results of Annual General Meeting

VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ:AUPH) (TSX:AUP) today announced the voting results from its annual general meeting (the “Meeting”) held on May 26, 2015.

A total of 24,371,491 shares were represented at the Meeting, being 75.54% of the Company’s issued and outstanding common shares. The shareholders voted on and approved all matters brought before the Meeting, including the election of the directors of the Company and the reappointment of PricewaterhouseCoopers LLP, Chartered Accountants as auditors of the Company.

Detailed results of the vote for the election of directors are provided below:

  Votes For       Votes Withheld
Nominee #   % #   %
Election of Directors
Richard Glickman 16,797,775 85.45 2,859,107 14.55
Stephen W. Zaruby 16,685,213 84.88 2,971,669 15.12
Benjamin Rovinski 19,655,289 99.99 1,593 0.01
Charles A. Rowland Jr. 19,655,369 99.99 1,513 0.01
David R.W. Jayne 19,655,338 99.99 1,544 0.01
Gregory M. Ayers 19,655,343 99.99 1,539 0.01
Hyuek Joon Lee 19,654,362 99.99 2,520 0.01

About Aurinia

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best in class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.

Company Contact:
Stephen W. Zaruby, 250-708-4293
President & Chief Executive Officer
szaruby@auriniapharma.com
or
Investor & Media Contact:
Michael R. Martin, 250-708-4272
Chief Operating Officer
mmartin@auriniapharma.com

Source: Aurinia Pharmaceuticals Inc.